$59.55
-0.72%Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Thin margins leave little room for error. Cost management and pricing strategy are critical.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
CNC โข NYSE
| Centene Corporation Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
194.8B | 163.1B | 154B | 144.5B | 126B | 111.1B | 74.6B | 60.1B | 48.4B | 40.6B | 22.8B | 16.6B | 10.9B | 8.1B | 5.2B | 4.4B | 4.1B | 3.4B | 2.8B | 2.3B | |
GROSS PROFIT | ||||||||||||||||||||
(170.9B) | (146.2B) | (136.7B) | (127.9B) | (111.8B) | (95.9B) | (65.8B) | (51.7B) | (42.6B) | (35.1B) | (20B) | (14.7B) | (9.7B) | (7.3B) | (4.4B) | (3.8B) | (3.2B) | (2.7B) | (2.3B) | (1.9B) | |
23.8B | 16.8B | 17.3B | 16.7B | 14.2B | 15.2B | 8.8B | 8.4B | 5.8B | 5.5B | 2.7B | 1.9B | 1.2B | 813M | 781.7M | 634.8M | 878.6M | 667.3M | 516.8M | 398.5M | |
OPERATING INCOME | ||||||||||||||||||||
(31.5B) | (13.7B) | (14.4B) | (15.3B) | (12.4B) | (12.1B) | (7.1B) | (7B) | (4.6B) | (4.3B) | (2B) | (1.4B) | (931M) | (705M) | (577.9M) | (477.8M) | (740.4M) | (535.7M) | (461.5M) | (427.4M) | |
(13.3B) | (12.4B) | (12.6B) | (11.6B) | (9.6B) | (11.3B) | (6.5B) | (6.8B) | (4.4B) | (4.1B) | (2B) | (1.4B) | (931M) | (677M) | (577.9M) | (477.8M) | (514.5M) | (444.7M) | (385M) | (346.3M) | |
-7.6B | 3.2B | 2.9B | 1.3B | 1.8B | 3.1B | 1.8B | 1.5B | 1.2B | 1.3B | 705M | 464M | 277M | 108M | 203.8M | 157.1M | 138.1M | 131.6M | 55.2M | -28.9M | |
PRE-TAX INCOME | ||||||||||||||||||||
(678M) | (702M) | (725M) | (665M) | (665M) | (728M) | (412M) | (343M) | (255M) | (217M) | (43M) | (35M) | (27M) | (20M) | (20.3M) | (18M) | (16.3M) | (16.7M) | (15.6M) | (10.6M) | |
-678M | -702M | -725M | -665M | -665M | -728M | -412M | -343M | -255M | -217M | -43M | -35M | -27M | -20M | -20.3M | -18M | -16.3M | -16.7M | -15.6M | -10.6M | |
(18.2B) | (1.3B) | (1.8B) | (3.7B) | (2.8B) | (791M) | (529M) | (211M) | (156M) | (147M) | (24M) | (16M) | (0.0) | (28M) | (0.0) | (0.0) | (225.9M) | (91M) | (76.6M) | (81.1M) | |
890.4M | 1.1B | 668M | 644M | 29M | -309M | 1M | -90M | -65M | -103M | -8M | -7M | -8M | 15M | -15.5M | -2.8M | -627K | 5.1M | 8.8M | 7.3M | |
-6.7B | 4.3B | 3.6B | 2B | 1.8B | 2.8B | 1.8B | 1.4B | 1.1B | 1.2B | 697M | 457M | 269M | 123M | 188.4M | 154.3M | 137.5M | 136.6M | 64.1M | -21.7M | |
NET INCOME | ||||||||||||||||||||
-51M | (963M) | (899M) | (760M) | (477M) | (979M) | (473M) | (474M) | (326M) | (599M) | (339M) | (196M) | (107M) | (47M) | (70.7M) | (59.9M) | (48.8M) | (52.4M) | (23M) | (22M) | |
-6.7B | 3.3B | 2.7B | 1.2B | 1.3B | 1.8B | 1.3B | 900M | 828M | 562M | 355M | 271M | 165.1M | 2M | 111.2M | 94.8M | 83.7M | 83.5M | 73.4M | -43.6M |
CNC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 15, 2026 | May 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 28, 2026 | April 28, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 28, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 26, 2026 | May 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 24, 2026 | March 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 10, 2026 | March 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 17, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 06, 2026 | February 06, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 10, 2025 | November 10, 2025 | 2025 |
Continue your CNC research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.